Antimicrobial resistance (AMR) happens when microorganisms, in this case bacteria,  adapt to and become resistant to antibiotics. This is a natural defense mechanism that microorganisms undertake to insure survival of the species.  As a result of years of abuse and over-prescribing, most currently available antibiotics have become ineffective and infections caused by the resistant pathogens have become a serious global problem threatening world economies and resulting in over 700,000 deaths each year globally.  According to the Tackling Drug-Resistant Infections Globally report1, it is estimated that by the year 2050, over 10,000,000 people will die annually from AMR infections.  The cost of antimicrobial resistance to the economy is staggering.  It is estimated that if no action is taken now to stop the threat of AMR, the global economy will have paid over 100 trillion dollars between now and 2050 to manage AMR infections. The situation is made worse by the apparent lack of interest in developing new antibiotics by the world’s large pharmaceutical companies.  Therefore, the need for new antibiotics to treat resistant pathogens is critical and immediate.

​

Fedora is committed to applying the company’s 100+ years of cumulative experience in anti-infectives research to the development of novel antibiotics targeting Gram-negative and Gram-positive microbes. Among those areas of interest are the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), which the World Health Organization has identified as the most critical unmet needs.